3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
6
Phase 2
3
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
74
Colonic Neoplasms
31
Rectal Neoplasms
29
Neoplasm Metastasis
15
Stomach Neoplasms
12
Pancreatic Neoplasms
11
Small Cell Lung Carcinoma
7
Esophageal Squamous Cell Carcinoma
7
Neoplasms
6
Esophageal Neoplasms
6
Rhabdomyosarcoma
4
Intestinal Neoplasms
4
Gastrointestinal Neoplasms
4
Digestive System Neoplasms
4
Uterine Cervical Neoplasms
3
Sarcoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Cholangiocarcinoma
3
Biliary Tract Neoplasms
3
Rectal Diseases
2
Neuroblastoma
2
Neoplasms by Histologic Type
2
Intestinal Diseases
2
Hepatoblastoma
2
Gastrointestinal Diseases
2
Ganglioneuroblastoma
2
Digestive System Diseases
2
Colorectal Cancer Metastatic
2
Colorectal Adenocarcinoma
2
Colonic Diseases
2
Interventions
Gemcitabine
13
Cisplatin
10
Capecitabine
7
pembrolizumab
3
Oxaliplatin
3
Leucovorin
3
Chemotherapy, Adjuvant
3
durvalumab
2
Watchful Waiting
2
Fluorouracil
2
Dihematoporphyrin Ether
2
zanidatamab
1
becatecarin
1
Tegafur
1
Taxes
1
Somatostatin
1
S 1 (combination)
1
Platinum
1
Phototherapy
1
Photochemotherapy
1
Ondansetron
1
Neoadjuvant Therapy
1
Laser Therapy
1
Irinotecan
1
Folfox protocol
1
Fentanyl
1
Escitalopram
1
Epirubicin
1
Dexamethasone
1
Chemoradiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Gallbladder Neoplasms
×
Irinotecan
×
Clear all
NCT07265674
2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3
Recruiting
480 enrolled